The contract research organisation (CRO) said their new establishment will allow them to enter into contractual agreements in Israel.
Armand Czaplinski, Executive Director Global Country Management, at Chiltern told Outsourcing-Phama the new entity will give them the ability to increase headcount easily therefore “meeting the needs of our strategic clients.”
He said: “Having a legal entity in Israel allows us to enter into contractual agreements and through the legal entity, we will be able to increase our headcount easily and to better serve our clients’ needs in this region.
“Israel is an attractive location to conduct clinical trials for drug development and medical devices as it has many key opinion leaders (KOL) in clinical research and outstanding quality of research. Israel has some of the most skilled and educated work forces with the highest number of doctors, scientists and engineers per capita than any other country. “
Czaplinski added: “Another key advantage is that the majority of Israel’s population belongs to the same health maintenance organization and this facilitates quick start for clinical trials and reduces the overall project timelines.”
Movers and shakers
Chiltern is the latest to front the queue of CROs scrambling to establish roots in the ever-growing world of Israeli clinical trials.
In February, North Carolina-based PRA set up shop in Tel Aviv to meet an “increased demand for services in the Middle East and Europe.”
Whilst in May Clinspace bought Swiss firm PFC Pharma Focus with a view to expanding into the Middle East.